Equity to Asset ratio is calculated as total stockholders equity divided by total asset. WAVE Life Sciences's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $141.64 Mil. WAVE Life Sciences's Total Assets for the quarter that ended in Sep. 2024 was $358.50 Mil.
Therefore, WAVE Life Sciences's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.40.
The historical rank and industry rank for WAVE Life Sciences's Equity-to-Asset or its related term are showing as below:
WVE'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.31 Med: 0.31 Max: 0.93
Current: 0.4
During the past 11 years, the highest Equity to Asset Ratio of WAVE Life Sciences was 0.93. The lowest was -0.31. And the median was 0.31.
WVE's Equity-to-Asset is ranked worse than 71.95% of 1508
companies
in the Biotechnology industry
Industry Median: 0.67
vs WVE: 0.40
WAVE Life Sciences Equity-to-Asset Historical Data
The historical data trend for WAVE Life Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WAVE Life Sciences's Equity-to-Asset
For the Biotechnology subindustry, WAVE Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's Equity-to-Asset falls into.
WAVE Life Sciences Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
WAVE Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (NAS:WVE) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
WAVE Life Sciences Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of WAVE Life Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WVE has been successfully added to your 